Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shubhrat Maheshwari has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Carbon quantum dots in biomedical applications

    by Shubhrat Maheshwari, Aditya Singh, Jagatpal Yadav, Amita Verma

    Carbon quantum dots (CQDs) have emerged as an important class of carbon-based fluorescent nanomaterials owing to their tunable photoluminescence, favorable aqueous dispersibility, and modifiable surface chemistry, which support diverse biomedical applications. This review critically summarizes recent advances in biofabricated CQDs with particular emphasis on green synthesis approaches, physicochemical characterization, surface engineering, and biomedical performance. Various synthesis strategies, including hydrothermal, microwave-assisted, electrochemical, and biomass-derived methods, are comparatively evaluated in terms of scalability, reproducibility, biocompatibility, and translational potential. In addition, the biomedical applications of CQDs in bioimaging, biosensing, targeted drug delivery, cancer theranostics, and antimicrobial platforms are comprehensively discussed with recent literature updates. The influence of surface functionalization on colloidal stability, targeting efficiency, cellular uptake, and biological interactions is also examined. Furthermore, current evidence from in vitro and in vivo studies regarding the biosafety and toxicity profiles of CQDs is critically analyzed. Despite significant progress, several challenges remain, including large-scale synthesis standardization, long-term toxicity evaluation, batch-to-batch reproducibility, and regulatory limitations associated with clinical translation. Future advancements in scalable fabrication techniques, multifunctional surface engineering, and safety assessment strategies may accelerate the development of CQDs-based nanomedicine platforms for diagnostic and therapeutic applications.

  • Emerging diagnostic biomarkers and therapeutic targets in Alzheimer's disease

    by Thumbar Kishan Dineshbhai, Dhvani Rafaliya, Aditya Singh, Shubhrat Maheshwari, Manisha Lalan, Guno Sindhu Chakraborthy


  • Open Access

    Quality-by-Design-Based Development and Optimization of Emtricitabine-Loaded Solid Lipid Nanoparticles

    by Shubhrat Maheshwari, Aditya Singh, Amita Verma

    Background: Emtricitabine (FTC) is a nucleoside reverse transcriptase inhibitor widely used in combination antiretroviral therapy for HIV infection. Its pharmacokinetic characteristics and need for regular dosing may affect patient adherence. Solid lipid nanoparticles (SLNs) have been considered beneficial in terms of drug entrapment and drug delivery. The study was conducted using a Quality-by-Design (QbD) strategy along with Box–Behnken Design (BBD) in order to optimize FTC-loaded SLNs systematically. Methods: A three-variable, three-level Box-Behnken Design consisting of seventeen runs has been employed to investigate the effects of stearic acid concentration, Tween 80 concentration, and homogenization speed on the entrapment efficiency of FTC. Results: The optimized quadratic model exhibited exceptional predictive ability (R² =0.9989, adjusted R² = 0.9976, predicted R² = 0.9867), along with a non-significant lack of fit (p = 0.1047). It was found that stearic acid had the highest positive effect on EE%, while an increase in Tween 80 concentration and homogenization speed reduced the drug entrapment significantly. Results from the numerical optimization indicated that the optimized formulation had 164.68 mg of stearic acid, 2.09% of Tween 80 concentration, and a homogenization speed of 12,074.8 rpm, which yielded an EE% of 85.32%. Experimental validation indicated an EE% of 85.28%, which matched quite closely with the predicted value, yielding a prediction bias of 0.047%. Conclusion: The QbD-driven BBD method developed a reliable and statistically valid optimization method for SLNs loaded with FTC. The optimization study provided an effective formulation with high entrapment efficiency and corroborated the reliability of the approach employed, leading to promising possibilities for the physical and chemical characterization, controlled release assessment, and future reproduction of emtricitabine-loaded lipid formulations. Keywords – Emtricitabine[FTC]; Solid lipid Nanoparticles[SLNs]; Quality by Design[QbD]; Entrapment efficiency; Box-Behnken design [BBD]; Nanocarrier optimization.

  • Open Access

    Advances in Lyotropic Liquid Crystals: Structure, Preparation, and Drug Delivery Potential

    by Jay Sonigara, Preet Gandhi, Mihir Solanki, Aditya Singh, Shubhrat Maheshwari

    Nanostructured self-assembling materials known as lyotropic liquid crystals (LLCs) consist of amphiphilic molecules in a solvent and having a number of mesophases such as cubic, hexagonal, and lamellar phases. Since LLCs are concentration-dependent and not temperature-dependent as it is the case with thermotropic liquid crystals, they are heavily applied in drug delivery, nanotechnology, and the biological sciences. Their ability to entrap hydrophilic and hydrophobic molecules supports controlled and site-specific drug release, promoting therapeutic efficacy and bioavailability. Stimuli-sensitive LLC systems have been found promising as devices for transdermal delivery, ocular delivery of drugs, and cancer therapy due to their sensitivity towards pH changes, temperature changes, or mechanical stress. Characterization techniques such as polarized light microscopy (PLM) and small-angle X-ray scattering (SAXS) are often employed to determine phase structures in order to understand their structural properties and enhance their formulations. Dynamic light scattering (DLS) helps in assessing colloidal stability. The fundamental concepts, types, compositions, and preparation methods—such as top-down and bottom-up strategies—of LLCs are all discussed elaborately in this article. It also addresses new advances in biomedical applications, control release strategies, targeted drug delivery systems, and their application to drug delivery. In addition, several case studies related to LLC formulations laden with anti-tumor drugs and their therapeutic capability are discussed. Formulation developments in LLC form are capable of reshaping present day drug delivery procedures and enhance therapeutic outcomes in biomedical applications.

  • Open Access

    Microencapsulation of Ranitidine Hydrochloride for Controlled Release Drug Formulation

    by Darshil Vaylu, Bhargavi Chaudhary, Ark Patel, Aditya Singh, Shubhrat Maheshwari

    The present study explored the microencapsulation of ranitidine hydrochloride to develop a controlled-release formulation aimed at improving bioavailability, reducing dosing frequency, and enhancing drug stability. Ranitidine, a H₂-receptor antagonist, is commonly used in the treatment of gastrointestinal disorders such as acid reflux, peptic ulcers, and Zollinger–Ellison syndrome. However, its conventional formulations are limited by a short half-life, poor stability, and the potential formation of N-nitrosodimethylamine (NDMA), a probable human carcinogen. To overcome these limitations, microencapsulation was employed using polymers such as Hydroxypropyl Methylcellulose (HPMC) and Microcrystalline Cellulose (MCC 102). The drug–polymer mixture was prepared using the extrusion–spheronization technique, followed by spray drying and pelletization. Various formulations were optimized by altering the drug-to-polymer ratio and solvent system (isopropyl alcohol and water). The prepared microcapsules and pellets were evaluated for physicochemical properties, including particle size, morphology, encapsulation efficiency, zeta potential, and surface characteristics using UV–Visible spectrophotometry, dynamic light scattering (DLS), and scanning electron microscopy (SEM). In vitro dissolution studies demonstrated a sustained drug release profile, which followed zero-order and Higuchi kinetic models, indicating controlled drug release behavior. The microencapsulation approach effectively minimized the degradation of ranitidine and ensured a more consistent release under simulated gastric conditions. Compatibility and stability studies further confirmed that HPMC and MCC-based formulations provided enhanced protection against hydrolysis and environmental stress. Overall, the findings suggest that microencapsulation is a promising strategy for reformulating ranitidine, offering improved therapeutic efficacy, controlled drug release, and better patient compliance. This study also provides a foundation for extending microencapsulation approaches to other drugs with short half-lives or stability concerns.

  • Open Access

    Optimization and Formulation of Emtricitabine-Loaded Liposomes Using a Box-Behnken Design

    by Ratanlal Vishwakarma, Shubhrat Maheshwari, Aditya Singh, Amita Verma

    Objective: The goal of this study was to use a Quality by Design (QbD) approach to create and improve liposomal formulations of Emtricitabine, an anti-HIV drug, to make it better at trapping other substances. Methods: A Box-Behnken Design (BBD) with three factors and three levels was used to systematically look at how the independent variables- Soy Lecithin (60–70%), Cholesterol (20–30%), and Palmitic Acid (5–10%)—affected the dependent variable, Entrapment Efficiency (EE %). We made and tested fifteen different formulas. Results: The statistical analysis of the BBD indicated that a Linear model was sufficient to describe the design space, as higher-order models were not significant. The ANOVA for the linear model yielded an F-value of 1.00 (p=0.4289), signifying that the model was not significant in relation to noise. None of the individual factors (Soy Lecithin, p=0.5831; Cholesterol, p=0.2393; Palmitic Acid, p=0.3099) demonstrated a statistically significant effect on EE within the studied ranges. However, the lack of fit was non-significant (p=0.9515), confirming the model's adequacy. A confirmation batch prepared with 70% Soy Lecithin, 20% Cholesterol, and 10% Palmitic Acid yielded an EE of 66.96%, which was within the 95% prediction interval (53.21% - 81.30%) of the predicted value (67.25%). Conclusion: Liposomal formulation of Emtricitabine was optimised and prepared with significant entrapment efficiency, which made possible to test it further through in vitro and in vivo studies. Keywords: Emtricitabine, Liposomes, Box-Behnken Design, Entrapment Efficiency, Quality by Design, Optimization, Anti-HIV.


  • Superparamagnetic iron oxide nanoparticles (SPIONs) in targeting brain tumors: advances and challenges

    by Shubhrat Maheshwari, Aditya Singh, Amita Verma, Mohammad Shariq, Juber Akhtar, Omar Awad Alsaidan, Bhupendra G. Prajapati

    Brain tumors are among the most lethal forms of cancer, often presenting treatment challenges due to the complexity of the central nervous system and the restrictive nature of the blood–brain barrier (BBB). Superparamagnetic iron oxide nanoparticles (SPIONs) have emerged as promising agents in neuro-oncology due to their unique magnetic properties, biocompatibility, and multifunctional capabilities. SPIONs serve as potent contrast agents in magnetic resonance imaging (MRI), drug delivery vehicles, and hyperthermia mediators. Their ability to be functionalized with ligands and antibodies allows for targeted delivery, minimizing systemic toxicity and enhancing therapeutic precision. Moreover, SPIONs have shown potential in modulating immune responses, disrupting tumor microenvironments, and improving the delivery of chemotherapeutics across the BBB. Despite encouraging preclinical outcomes and some early-phase clinical trials, challenges such as biodistribution control, toxicity, and manufacturing scalability remain. This review highlights the current landscape of SPION applications in brain tumor therapy and diagnosis, elaborating on their synthesis, functionalization, and translational hurdles. We also discuss future directions, including AI-guided theranostics, personalized nanomedicine, and integration with immunotherapy, aiming to illuminate the path forward for SPION-based clinical interventions. Graphical Abstract SPIONs for Diagnosis and Therapy of Brain Tumors


  • Open Access

    TLC Profiling and Phytochemical Evaluation of Kaempferia parviflora Rhizome: A Rich Source of Bioactive Metabolites

    by Swati Pandey, Shubhrat Maheshwari, Jagat Pal Yadav, Amita Verma

    The present study investigates the phytochemical composition and chromatographic profiling of the hydroalcoholic extract of Kaempferia parviflora rhizome. Preliminary phytochemical screening revealed the presence of key secondary metabolites including alkaloids, flavonoids, tannins, phenolics, saponins, steroids, glycosides, terpenoids, and volatile oils, supporting the plant's ethnomedicinal significance. Thin Layer Chromatography (TLC) analysis was performed using four solvent systems of varying polarity to optimize the separation and visualization of constituent compounds. Distinct and well-resolved bands were observed under UV light (254 nm and 365 nm), with Rf values ranging from 0.08 to 0.97, indicating a rich diversity of polar and moderately polar phytochemicals. Derivatization with vanillin-sulfuric acid further confirmed the presence of compound classes such as flavonoids, phenolics, terpenoids, and glycosides. The comprehensive phytochemical and chromatographic profiles obtained in this study underscore the potential of K. parviflora as a valuable phytopharmaceutical candidate, laying the groundwork for further bioactivity-guided isolation and anticancer assessment. Keywords: Kaempferia parviflora, Black ginger, Phytochemical analysis, TLC analysis, hydroalcoholic extract.

  • Nanomaterial in the Management of Diabetes

    by Shubhrat Maheshwari, Aditya Singh, Amita Verma, Juber Akhtar, Purba Mandal, Jagat Pal Yadav, Bhupendra G. Prajapati


  • Open Access

    Monkeypox: Advances in Understanding, Spread, and Management

    by Aditya Singh, Shubhrat Maheshwari, Rajesh Nath, Abhishek Kumar

    The infectious agent responsible for monkeypox is the Monkeypox Virus (MPXV), a family member of the Poxviridae genus of viruses. Mpox, formerly endemic to West and Central Africa, has had a notable increase in incidence beyond these countries since 2017, resulting in its resurgence as a global health issue. This review provides a comprehensive analysis of MPXV’s virology, epidemiology, and clinical management. MPXV is genetically similar to the variola virus, the causative agent of smallpox, with a genomic similarity of 96.3%. Despite this, notable differences in virulence and host range exist. Infected animals can infect humans through direct touch or their excretions; the virus mostly affects rodents and small mammals. A possible factor in the rise of mpox has been the end of smallpox immunization. Symptoms such as a rash, fever, headache, and myalgia are part of the clinical presentation. Although no specific antiviral drugs are approved for mpox, treatments like tecovirimat, cidofovir, and brincidofovir are used in severe cases. Smallpox vaccination offers cross-protection against mpox. Effective management involves diagnosis through PCR assays, symptomatic relief, isolation, and stringent hygiene practices. Public health measures are crucial for controlling outbreaks.